Research notes

4Q cash flow was again disappointing due to both execution and markets. The reasons driving further sales deferrals – possibly losses – again concern. CRN trades cheaply at (0.87x P/NPV reflecting higher operating risks in recent years and higher balance sheet leverage vs peers. CRN’s appeal for leverage to upside risks in coking coal pricing currently looks challenged by tepid steel markets which pose risks to lower rank met coals around realization and potentially incremental volume in our view.

M7T has provided a trading update, highlighting an acceleration of trend toward subscription style contracts and away from upfront capital sales. Being paid in installments comes at a near-term cost however, with recognition of these revenues shifting over the life of the contract which is often five years versus the one-and-done upfront sugar hit. A hit this year, but reap the rewards for the next five years. We have long viewed this as a necessary move which will result in a more sustainable and investor friendly business model which more closely resembles that of market darling Pro Medicus. While optically this would appear as a downgrade, the shift supports the valuation over the medium to long term. As a result of our recurring/capital sales weighting changes, our DCF valuation rises marginally to A$1.56ps from A$1.54ps. Add recommendation maintained.

We got this one wrong. We thought it possible that Domino’s would snap its streak of missing estimates in 1H24 and deliver a return to growth as sales momentum continued to recover. Domino’s issued a trading update that indicated same store sales have gapped down in Japan, weighing on group earnings and calling into question the strength of the consumer proposition in that market. 1H24 PBT will be $87-90m, below our forecast of $100m and consensus of $103m. We still believe Domino’s will get back to steady same store sales growth and network expansion in time, but it’s taking longer than we expected and the shares are likely to underperform for a while until the company has regained investor confidence. We downgrade from Add to Hold with a $50.00 target price (was $61.00).

Canada has announced a two-year cap on new International student visas, expecting to reduce CY24 approvals by ~35% vs CY23. In isolation, earnings impacts from tightening migration and international student policy settings across the major destinations; and visa changes impacting IELTs volumes are manageable. In aggregate, we expect a lower med-term growth profile. The UK election (2HCY24) arguably increases policy risk in the UK. We expect IEL to report a strong 1H24 result, driven by the strength in Student Placement (SP), partially offset with weaker IELTs volume. This composition is arguably weaker, forward looking, given the softening SP growth outlook. IEL continues to offer strong long-term growth. However, we expect uncertainty on announced (and potential) policy change impacts to weigh on the stock. Despite a strong upcoming result, we move to Hold, preferring to have increased confidence in med-term (FY25) earnings at this stage.

4Q production again proved strong but we’re cautious re approaching wet weather. We make several adjustments, trimming our valuation/ target slightly to $4.20ps. Introduction of dividends strongly builds SMR’s appeal to a wider investor base. We maintain an Add, but do note upside has narrowed on SMR’s re-rating. 1H Sales disruption and tepid steel markets could easily uncover better value.

NAN released a negative trading update, citing hospital budgetary pressures deferring purchasing decisions around new and replacement Trophon units. The timing of the update was surprising to us, and while market trust has clearly diminished following the announcement, we expect management to navigate and adjust as needed. The key will be more detailed guidance at the February result, and while we see the stock as deserving of a de-rate, we continue to see significant value in the install base, superiority over competitors, and Coris potential. Our target price reduces to A$3.88 and we retain our Add recommendation.

COE posted a solid 2Q’FY24 production and sales result, while a budget blowout at BMG increases the short-term drag on COE’s balance sheet. 2Q24 group production was 5.68PJe (vs MorgE/consensus 5.4/5.5PJe). New record daily production rate reached at Orbost of 67tj/d. Increased BMG abandonment budget of A$240-$280m (was A$193-$198m). We maintain an Add rating, with an A$0.25ps target price (was A$0.26).

KAR has provided an operational update following clearing of the hydrate issue at the SPS88 well, and subsequent mechanical failure. The surface issues are expected to persist until Q4’CY24, with a backlog on regulator approvals currently in Brazil delaying the work required to fix SPS88. KAR has revised CY24 group production guidance to 11.2-13.5mmboe (vs MorgE 12.6mmboe). We maintain an Add rating, with an updated A$2.80ps target price (previously A$2.95).

GDG’s 2Q24 quarterly update saw a strong Investment bond (IB) sales performance of ~A$156m (+37% on the pcp), albeit with netflows below our expectations (+A$91m versus +A$106m) on higher outflows.  The standout in the quarterly was the very strong IB investment performance (+A$140m), which helped drive FUM up a healthy ~9% over the period. We lift our GDG FY24F/FY25F EPS by 1%-3% on higher IB FUM forecasts in all years. Our target price is set at A$2.01 (previously A$1.91). We continue to believe GDG is well positioned to execute a compound earnings growth story over time. ADD maintained.

JDO released its unaudited 1H24 result and outlook for 2H24 (and into FY25), which were ahead of expectations. We make material upgrades to forecasts to align with performance and outlook. 12 month target price lifted 8% to $1.50/share, due to forecast changes. ADD.